Advertisement
Person › Details
Marc Dunoyer (AstraZeneca plc (LSE: AZN))
Dunoyer, Marc (AstraZeneca 201311– CFO joined 201303 as EVP Global Portfolio + Product Strategy before GSK)
Organisation | AstraZeneca plc (LSE: AZN) | |
Group | AstraZeneca (Group) | |
Former/major organisation | GlaxoSmithKline plc (LSE: GSK, NYSE: GSK) | |
Today | GSK plc (LSE: GSK, NYSE: GSK) | |
Group | GSK (Group) | |
Product | pharmaceutical | |
Product 2 | DRUGS, ORPHAN | |
Record changed: 2024-03-20 |
Advertisement
More documents for Marc Dunoyer
- [1] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
- [2] LogicBio Therapeutics, Inc.. (10/3/22). "Press Release: Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine". Lexington, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top